Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Finding Study of CycloSam® (153-Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewing's Sarcoma, and Other Solid Tumor(s) to the Bone All Eligible)

NCT06008483 is registered in ClinicalTrials.gov with QSAM Therapeutics, Inc. as lead sponsor.

NCT NCT06008483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06008483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Finding Study of CycloSam® (153-Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewing's Sarcoma, and Other Solid Tumor(s) to the Bone All Eligible)
Lead sponsor
QSAM Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
April 5, 2022
Completion date
August 8, 2024
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bone cancer, bone tumor, metastatic cancer to the bone, metastatic tumor to the bone, solid tumor